Cheryl Lobo

Dr. Cheryl Lobo

Department of Blood-Borne Parasites, Lindsley Kimball Research Institute, New York Blood Center, New York, NY 10065, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YLYunfeng Liu
Yunfeng Liu
SSShan Su
Shan Su
SSSarah Shayo
Sarah Shayo
WBWeili Bao
Weili Bao
MPMouli Pal
Mouli Pal
KYKarina Yazdanbakhsh
Karina Yazdanbakhsh
Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by painful vaso-occlusive crises (VOC) and chronic hemolysis. The mononuclear phagocyte system is pivotal to SCD pathophysiology, but the mechanisms governing monocyte/macrophage differentiation remain unknown. This study examined the influence of hemolysis on circulating monocyte trajectories in SCD. We discovered that hemolysis stimulated CSF-1 production, partly by endothelial cells via Nrf2, promoting classical monocyte (CMo) differentiation into blood patrolling monocytes (PMo) in SCD mice. However, hemolysis also upregulated CCL-2 through IFN-I, inducing CMo transmigration and differentiation into tissue monocyte–derived macrophages. Blocking CMo transmigration by anti–P selectin antibody in SCD mice increased circulating PMo, corroborating that CMo-to–tissue macrophage differentiation occurs at the expense of CMo-to–blood PMo differentiation. We observed a positive correlation between plasma CSF-1/CCL-2 ratios and blood PMo levels in patients with SCD, underscoring the clinical significance of these two opposing factors in monocyte differentiation. Combined treatment with CSF-1 and anti–P selectin antibody more effectively increased PMo numbers and reduced stasis compared with single-agent therapies in SCD mice. Altogether, these data indicate that monocyte fates are regulated by the balance between two heme pathways, Nrf2/CSF-1 and IFN-I/CCL-2, and suggest that the CSF-1/CCL-2 ratio may present a diagnostic and therapeutic target in SCD.

27 February 2025 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CGChengjie Gao
Chengjie Gao
YDYitian Dai
Yitian Dai
PSPaul A. Spezza
Paul A. Spezza
PBPaul Boasiako
Paul Boasiako
ATAlice Tang
Alice Tang
AMAvital Mendelson
Avital Mendelson
Newly produced platelets acquire a low activation state, but whether the megakaryocyte plays a role in this outcome has not been fully uncovered. Mesenchymal stem cells (MSCs) were previously shown to promote platelet production and lower platelet activation. We found that healthy megakaryocytes transfer mitochondria to MSCs, which is mediated by connexin 43 (Cx43) gap junctions on MSCs and leads to platelets at a low energetic state with increased LYN activation, characteristic of resting platelets with increased LYN activation, characteristic of resting platelets. On the contrary, MSCs have a limited ability to transfer mitochondria to megakaryocytes. Sickle cell disease (SCD) is characterized by hemolytic anemia and results in heightened platelet activation, contributing to numerous disease complications. Platelets in SCD mice and human samples had a heightened energetic state with increased glycolysis. MSC exposure to heme in SCD led to decreased Cx43 expression and a reduced ability to uptake mitochondria from megakaryocytes. This prevented LYN activation in platelets and contributed to increased platelet activation at steady state. Altogether, our findings demonstrate an effect of hemolysis in the microenvironment leading to increased platelet activation in SCD. These findings have the potential to inspire new therapeutic targets to relieve thrombosis-related complications of SCD and other hemolytic conditions.

7 October 2022 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
DBDivya Beri
Divya Beri
MRMarilis Rodriguez
Marilis Rodriguez
MSManpreet Singh
Manpreet Singh
YLYunfeng Liu
Yunfeng Liu
GRGiselle Rasquinha
Giselle Rasquinha
CLCheryl Lobo
Cheryl Lobo
Babesiosis is a zoonosis and an important blood-borne human parasitic infection that has gained attention because of its growing infection rate in humans by transfer from animal reservoirs. Babesia represents a potential threat to the blood supply because asymptomatic infections in man are common, and blood from such donors can cause severe disease in certain recipients. Extracellular vesicles (EVs) are vesicles released by cells that contain a complex mixture of proteins, lipids, glycans, and genetic information that have been shown to play important roles in disease pathogenesis and susceptibility, as well as cell–cell communication and immune responses. In this article, we report on the identification and characterization of EVs released from red blood cells (RBCs) infected by two major human Babesia species—Babesia divergens from in vitro culture and those from an in vivo B. microti mouse infection. Using nanoparticle tracking analysis, we show that there is a range of vesicle sizes from 30 to 1,000 nm, emanating from the Babesia-infected RBC. The study of these EVs in the context of hemoparasite infection is complicated by the fact that both the parasite and the host RBC make and release vesicles into the extracellular environment. However, the EV frequency is 2- to 10-fold higher in Babesia-infected RBCs than uninfected RBCs, depending on levels of parasitemia. Using parasite-specific markers, we were able to show that ~50%–60% of all EVs contained parasite-specific markers on their surface and thus may represent the specific proportion of EVs released by infected RBCs within the EV population. Western blot analysis on purified EVs from both in vivo and in vitro infections revealed several parasite proteins that were targets of the host immune response. In addition, microRNA analysis showed that infected RBC EVs have different microRNA signature from uninfected RBC EVs, indicating a potential role as disease biomarkers. Finally, EVs were internalized by other RBCs in culture, implicating a potential role for these vesicles in cellular communication. Overall, our study points to the multiple functional implications of EVs in Babesia–host interactions and support the potential that EVs have as agents in disease pathogenesis.

16 February 2017 in Cytometry Part A
Verified
Journal Article
Closed access
PDF file
JCJeny R. Cursino‐Santos
Jeny R. Cursino‐Santos
MSManpreet Singh
Manpreet Singh
PPPetra Pham
Petra Pham
CLCheryl Lobo
Cheryl Lobo

25 March 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
EMEstrella Montero
Estrella Montero
JGJeremy Gray
Jeremy Gray
CLCheryl Lobo
Cheryl Lobo
LGLuis Miguel González
Luis Miguel González
Babesia is a genus of intraerythrocytic protozoan parasites belonging to the exclusively parasitic phylum Apicomplexa

22 August 2019 in JCI Insight
Verified
Journal Article
Open access
PDF file
AMAvital Mendelson
Avital Mendelson
ASAna Nicolle Strat
Ana Nicolle Strat
WBWeili Bao
Weili Bao
PRPeter Rosston
Peter Rosston
GFGeorgia Fallon
Georgia Fallon
KYKarina Yazdanbakhsh
Karina Yazdanbakhsh
The complex process of platelet formation originates with the hematopoietic stem cell, which differentiates through the myeloid lineage, matures, and releases proplatelets into the BM sinusoids. How formed platelets maintain a low basal activation state in the circulation remains unknown. We identify Lepr + stromal cells lining the BM sinusoids as important contributors to sustaining low platelet activation. Ablation of murine Lepr + cells led to a decreased number of platelets in the circulation with an increased activation state. We developed a potentially novel culture system for supporting platelet formation in vitro using a unique population of CD51 + PDGFRα + perivascular cells, derived from human umbilical cord tissue, which display numerous mesenchymal stem cell (MSC) properties. Megakaryocytes cocultured with MSCs had altered LAT and Rap1b gene expression, yielding platelets that are functional with low basal activation levels, a critical consideration for developing a transfusion product. Identification of a regulatory cell that maintains low baseline platelet activation during thrombopoiesis opens up new avenues for improving blood product production ex vivo.